Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study-Reference-Cited by-同舟云学术

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study

Published:2020-09-24 Issue:22 Volume:9 Page:8468-8479
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Cuneo Antonio¹,Mato Anthony R.²^ORCID,Rigolin Gian Matteo¹^ORCID,Piciocchi Alfonso³,Gentile Massimo⁴,Laurenti Luca⁵,Allan John N.⁶,Pagel John M.⁷,Brander Danielle M.⁸,Hill Brian T.⁹,Winter Allison⁹^ORCID,Lamanna Nicole¹⁰,Tam Constantine S.¹¹,Jacobs Ryan¹²,Lansigan Frederick¹³^ORCID,Barr Paul M.¹⁴,Shadman Mazyar¹⁵,Skarbnik Alan P.¹⁶,Pu Jeffrey J.¹⁷^ORCID,Sehgal Alison R.¹⁸,Schuster Stephen J.¹⁹,Shah Nirav N.²⁰^ORCID,Ujjani Chaitra S.¹⁵,Roeker Lindsey²,Orlandi Ester Maria²¹,Billio Atto²²,Trentin Livio²³,Spacek Martin²⁴,Marchetti Monia²⁵^ORCID,Tedeschi Alessandra²⁶,Ilariucci Fiorella²⁷,Gaidano Gianluca²⁸,Doubek Michael²⁹,Farina Lucia³⁰,Molica Stefano³¹^ORCID,Di Raimondo Francesco³²,Coscia Marta³³,Mauro Francesca Romana³⁴^ORCID,de la Serna Javier³⁵,Medina Perez Angeles³⁶,Ferrarini Isacco³⁷,Cimino Giuseppe³⁸,Cavallari Maurizio¹,Cucci Rosalba³,Vignetti Marco³,Foà Robin³⁴,Ghia Paolo³⁹,

Affiliation:

1. Hematology Department of Medical Sciences St. Anna University Hospital Ferrara Italy

2. Division of Hematological Oncology CLL ProgramMemorial Sloan Kettering Cancer Center New York NY USA

3. Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center and Health Outcomes Research Unit Rome Italy

4. Department of Onco‐Hematology Hematology UnitA.O. of Cosenza Cosenza Italy

5. Department of Radiological, Radiotherapeutic and Hematological Sciences Fondazione Policlinico Universitario “A. Gemelli” IRCCS Rome Italy

6. Weill Cornell Medicine New York NY USA

7. Center for Blood Disorders and Stem Cell Transplantation Swedish Cancer Institute Seattle WA USA

8. Division of Hematologic Malignancies and Cellular Therapy Duke University Durham NC USA

9. Taussig Cancer InstituteCleveland Clinic Cleveland OH USA

10. Columbia University Medical Center New York NY USA

11. Peter McCallum Cancer Centre University of Melbourne Melbourne Victoria Australia

12. Department of Hematologic Oncology and Blood Disorders Levine Cancer InstituteCarolinas Healthcare System Charlotte NC USA

13. Dartmouth‐Hitchcock Medical Center Lebanon NH USA

14. Wilmot Cancer InstituteUniversity of Rochester Medical Center Rochester NY USA

15. Fred Hutchinson Cancer Research CenterSeattle Cancer Care Alliance Seattle WA USA

16. Lymphoproliferative Disorders Program Novant Health Cancer Institute Charlotte NC USA

17. SUNY Upstate Medical UniversitySUNY Upstate Medical University Syracuse NY USA

18. University of Pittsburgh Pittsburgh PA USA

19. Division of Hematology and Oncology University of Pennsylvania Philadelphia PA USA

20. Division of Hematology & Oncology Medical College of Wisconsin Milwaukee WI USA

21. Hematology UnitIRCCS Policlinico San Matteo Pavia Italy

22. Hematology and Transplant Unit San Maurizio HospitalAzienda Sanitaria dell'Alto Adige Bolzano Italy

23. Hematology and Clinical Immunology Department of Medicine University of Padua Padua Italy

24. Department of Medicine Department of Hematology First Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

25. Oncology UnitCardinal Massaia Hospital Asti Italy

26. Hematology Niguarda Cancer CenterASST Grande Ospedale Metropolitano Niguarda Milan Italy

27. Hematology Azienda USL‐IRCCS Reggio Emilia Italy

28. Division of Hematology Department of Translational Medicine University of eastern Piedmont Novara Italy

29. Department of Internal Medicine ‐ Hematology and Oncology University Hospital Brno and Faculty of MedicineMasaryk University Brno Czech Republic

30. Hematology Department Fondazione IRCCS Istituto Nazionale Tumori Milano Italy

31. Hematology Unit A. Pugliese HospitalAzienda Ospedaliera Pugliese Ciaccio Catanzaro Italy

32. Catania Università di CataniaCattedra di Ematologia Catania Italy

33. Division of Hematology A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy

34. Hematology Department of Translational and Precision Medicine "Sapienza" University Rome Italy

35. Hematology Unit Hospital Universitario Madrid Spain

36. Hospital Costa del Sol Marbella Spain

37. Hematology Department of Cell Therapy and Hematology University Hospital Verona Italy

38. Department of Translational and Precision Medicine University “La Sapienza”UOC di Ematologia con TrapiantoOspedale S. Maria Goretti Latina Italy

39. Strategic Research Program on CLL Division of Experimental Oncology IRCCS Ospedale San RaffaeleUniversità Vita‐Salute San Raffaele Milan Italy

Funder

Ministero della Salute

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3470

Reference37 articles.

1. Cancer statistics, 2019

2. Altered treatment of chronic lymphocytic leukemia in Germany during the last decade

3. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

4. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

5. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ibrutinib in CLL: benefit for all?;Blood;2024-04-18

2. First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era;Cancers;2023-07-29

3. Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study;Blood Advances;2022-07-05

4. Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients;Current Oncology;2022-04-15

5. Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence;Journal of Clinical Medicine;2022-04-07